Target and Technology
SGN-CD48A is an antibody-drug conjugate (ADC) targeted to the protein CD48, a cell surface protein highly expressed in multiple myeloma. SGN-CD48A uses our latest ADC technology advancement, a next-generation PEGylated glucuronide linker that improves stability, reduces off-target uptake, and enables conjugation of more molecules of the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE) per antibody. SGN-CD48A is designed to be highly stable in circulation and release an increased amount of MMAE upon internalization into CD48-expressing cells, producing greater antitumor activity in preclinical studies.
ADC technology combines the specificity of monoclonal antibodies, innovative linker systems, and the cell killing power of potent cytotoxic agents to treat cancer. Using our proprietary industry-leading technology, we are able to optimize each ADC to potentially improve outcomes for patients.
Clinical Development Status
- Phase 1 trial evaluating the safety and tolerability of SGN-CD48A for patients with relapsed or refractory multiple myeloma